Federal Circuit Affirms-in-Part MediVis v. Novarad AR Medical Imaging Patent Ruling

Case Overview

The Parties

The Patent at Issue

At the heart of this dispute is U.S. Patent No. 11,004,271 B2 (Application No. US16/574524), assigned to MediVis. The patent claims technology directed at augmenting real-time views of a patient with three-dimensional data — essentially, the foundational capability of projecting pre-operative or intraoperative 3D imaging (such as CT or MRI data) onto a live patient view through an AR interface. This type of technology has direct applications in surgical navigation, minimally invasive procedures, and anatomical planning.

• • US 11,004,271 B2 — Augmenting real-time patient views with three-dimensional data

Litigation Timeline & Procedural History

The appeal was filed on May 7, 2024, with the Federal Circuit in the District of Columbia circuit jurisdiction, and concluded March 3, 2026 — a duration of 665 days from filing to close.

The case reached the Federal Circuit at the appellate level, indicating that the underlying patentability dispute had already been adjudicated at a lower tribunal — most likely the Patent Trial and Appeal Board (PTAB) or a district court — before being elevated on appeal. The verdict cause is identified as patentability, with the verdict cause summary categorized as an Invalidity/Cancellation Action, suggesting the core challenge involved an inter partes review (IPR) or post-grant proceeding attacking the validity of the ‘271 patent.

The 665-day appellate duration is notable. Federal Circuit appeals in patent cases average roughly 12 to 18 months from docketing to decision. A timeline approaching 22 months suggests the court gave this case meaningful deliberation — consistent with the complexity of a split outcome requiring partial affirmance, partial reversal, and remand on distinct claim groupings or legal issues.

The Verdict & Legal Analysis

Outcome

The Federal Circuit issued a three-part ruling: AFFIRMED-IN-PART, REVERSED-IN-PART, AND REMANDED. Specific damages amounts were not disclosed in the available case data. No injunctive relief disposition was recorded, which is consistent with patentability-focused appellate proceedings rather than direct infringement trials.

Key Legal Issues

The Federal Circuit’s analysis focused on **patentability** under an invalidity or cancellation action framework. In this context, the Federal Circuit likely reviewed determinations regarding whether claims of U.S. Patent No. 11,004,271 B2 were invalid on grounds such as obviousness (35 U.S.C. § 103), anticipation (35 U.S.C. § 102), or written description/enablement (35 U.S.C. § 112).

The split nature of the verdict — affirming some findings while reversing others and remanding — is characteristic of Federal Circuit decisions where different claim groupings receive different patentability outcomes. This pattern frequently arises when a PTAB final written decision cancels some patent claims while confirming others, and the Federal Circuit independently evaluates each determination under the substantial evidence standard.

The remand instruction indicates that at least one issue requires further factual development or legal analysis at the lower tribunal level, which may involve additional claim construction, a revised obviousness analysis, or reconsideration of specific prior art combinations.

Legal Significance

This ruling contributes to the growing body of Federal Circuit precedent on AR-based medical technology patents — a category where the intersection of software, imaging, and real-time data processing creates persistent validity challenges. The partial reversal signals that the Federal Circuit found legal error in at least one aspect of the lower tribunal’s patentability analysis, which may carry instructive value for how AR medical imaging claims should be constructed and defended.

For practitioners, the case reinforces that claim differentiation within a single patent family can produce divergent validity outcomes — and that prosecution history, claim scope, and prior art landscapes must be managed at a granular, claim-by-claim level.

Industry & Competitive Implications

The MediVis v. Novarad dispute reflects intensifying IP competition in the augmented reality medical imaging sector. As hospitals and surgical centers accelerate adoption of AR-guided procedures, the underlying patent landscape is becoming a strategic battleground for both startups and established imaging companies.

For MediVis, a partial Federal Circuit win preserves a meaningful portion of its patent portfolio and may support ongoing licensing discussions or future enforcement actions. For Novarad, the partial reversal provides potential leverage to narrow the scope of claims it must design around or license.

More broadly, this case signals that AR medical technology patents will face rigorous patentability scrutiny at both the PTAB and Federal Circuit levels. Companies building in this space should anticipate validity challenges and invest in prosecution strategies that build robust prior art differentiation into the application record from the outset.

The outcome also suggests an active licensing environment for AR surgical visualization IP, where split Federal Circuit decisions may accelerate settlement discussions by clarifying which claims carry genuine enforceability value.